Pyxis Oncology, Inc. Unrealized Gain (Loss) on Derivatives
Pyxis Oncology, Inc. (PYXS) reported Unrealized Gain (Loss) on Derivatives of -$6.23 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2023-03-22
- Pyxis Oncology, Inc. unrealized gain (loss) on derivatives for the quarter ending 2021-12-31 was -$12.05M.
- Pyxis Oncology, Inc. unrealized gain (loss) on derivatives for the quarter ending 2021-09-30 was $9.08M.
- Pyxis Oncology, Inc. unrealized gain (loss) on derivatives for the quarter ending 2021-06-30 was -$2.16M.
- Pyxis Oncology, Inc. unrealized gain (loss) on derivatives for the quarter ending 2021-03-31 was -$1.10M.
- Pyxis Oncology, Inc. unrealized gain (loss) on derivatives for fiscal 2021 was -$6.23M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 9 month as first filed | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | -$12.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$2.97M derived: sum of 2 quarters · filed 2023-03-22 | -$5.13M derived: sum of 3 quarters · filed 2023-03-22 | -$6.23M 10-K · filed 2023-03-22 | |
| 2021-09-30 | $9.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $6.92M derived: sum of 2 quarters · filed 2022-11-01 | $5.82M 10-Q · filed 2022-11-01 | -$5.82M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$3.26M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$1.10M 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |